Point well taken Mike. But as the drug is not available for general use yet, it's hard to see how it could be used to guide clinical practice.
The original trial was stopped (broken) due to the strength of data obtained. Studies are reviewed multiple times while they are still ongoing to monitor for adverse outcomes.
The studies will have been fully vetted prior to any approval for use outside clinical trials. At that time recommended dosing, schedule, and duration of treatment will be published.